Join to View Full Profile
UCSD Rancho Bernado16950 Via TazonSan Diego, CA 92127
Phone+1 800-926-8273
Dr. Yeang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Clinical Expertise
- Atherosclerosis, Preventive cardiology, Lipid metabolism disorders, Lipoprotein disorders, Lipoprotein(a)
Education & Training
University of California (San Diego) Medical CenterFellowship, Cardiovascular Disease, 2014 - 2019- UC San Diego Medical Center - HillcrestPost-Doctoral Fellowship, 2014 - 2019
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2012 - 2014
State University of New York Downstate Medical Center College of MedicineClass of 2012
Certifications & Licensure
CA State Medical License 2013 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.Harpreet S Bhatia, Matthew Ambrosio, Alexander C Razavi, Pamela L Alebna, Calvin Yeang
JAMA Cardiology. 2025-06-04 - Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort.Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd
Atherosclerosis. 2025-06-01 - 4 citationsThe Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk.Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A Bax, John W Eikelboom, Arend Mosterd
European Journal of Preventive Cardiology. 2024-10-30
Lectures
- Lp(a)-Cholesterol and True LDL-Cholesterol: Implications for Refining CVD Risk Attributed to LDL and Lp(a)Lipoprotein(a) Symposium, EAS endorsed satellite meeting - 5/24/2019
- The Role of Lp(a) in Calcific Aortic Valve Disease: Clinical and Basic Research EvidenceHeart Valve Society - 4/12/2018
Authored Content
- The Role of Lipoprotein(A) in Calcific AV Disease and Insights into Its Medical TherapiesApril 2020
- The Role of Lipoprotein(A) in Calcific AV Disease and Insights into Its Medical TherapiesApril 2020
- PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes with a Human Antibody Detects Clinically Relevant AtherothrombosisJanuary 2018
- PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes with a Human Antibody Detects Clinically Relevant AtherothrombosisJanuary 2018
- Join now to see all
Grant Support
- Defining the Role of Lipoprotein(a) and its Oxidized Phospholipids in the Development and Progression of Calcific Aortic Valve Disease Using Unique Transgenic Mouse ModelsNIH/NHLBI2020–2025
Professional Memberships
- Member
- Member
- European Atherosclerosis SocietyMember
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
